Table 1.
Clinical details of individuals included in this study
| Variable | HCt-noV | HCt-V | BPH | PCa-noV | PCa-V |
|---|---|---|---|---|---|
| Total, n | 9 | 5 | 5 | 16 | 8 |
| Age, mean ± SD (years) | 40.8±2.38 | 39.2±1.92 | 59.2±5.31 | 58.9±4.93 | 58.6±9.08 |
| Pre-biopsy PSA (n) | |||||
| ≤10 (ng/ml) | 9 | 5 | 5 | 13 | 5 |
| >10 (ng/ml) | 0 | 0 | 0 | 3 | 3 |
| Pre-biopsy PSA, mean ± SD (ng/ml) | nd | nd | 5.27±0.68 | 7.59±3.60 | 8.35±4.77 |
| Gleason score-biopsy (n) | |||||
| 6 (3+3) | nd | nd | nd | 8 | 5 |
| 7 (3+4) | nd | nd | nd | 4 | 3 |
| 7 (4+3) | nd | nd | nd | 3 | 0 |
| 8 (4+4) | nd | nd | nd | 1 | 0 |
| Clinical stage (n) | |||||
| cT1c | nd | nd | nd | 11 | 3 |
| cT2a | nd | nd | nd | 0 | 1 |
| cT2c | nd | nd | nd | 3 | 3 |
| cT3a | nd | nd | nd | 2 | 1 |
HCt: healthy control group; BPH: benign prostate hyperplasia group; PCa-noV: prostate cancer from non-vasectomized individuals; PCa-V: prostate cancer from vasectomized individuals. Text in italics refers to healthy individuals that were not analyzed for PSA. In this case, PSA levels were inferred from PSA reference values of healthy men based on age [32].